Skip to main content
Delfa

← All trials/NCT07834398

CompletedPhase 3

Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

Evaluating the Efficacy of Various Weekly GLP1receptor Agonist Among Obese Individuals Without Diabetes

Lead sponsor

Zagazig University

Assets

Dulaglutide / Semaglutide / Tirzepatide

Listed sites

1

Recruiting sites

-

Actual enrollment

150

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥30

Primary endpoint

•Body weight at 3 and 6 months

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07834398
Org study IDKACST,KSA:H-11-N-140

Timeline

Milestones

Study start2025-11-14actual
Primary completion2026-04-13actual
Study completion2026-04-21actual
Study first posted2026-09-22actual
Last update posted2026-09-22actual

Assets

Investigational agents

DulaglutideSemaglutideTirzepatide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Subjects (above 18 years old) obese body mass index (BMI) above 30

Exclusion criteria

•Subjects with liver disease, renal dysfunction diabetes, pancreatic diseases ,thyroid disorder or goiter psychological diseases like depression and pregnant women, and Patients who will refuse

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
4
Weight & body composition
2
MASH / liver
2
Glycemic / diabetes
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

change in body weight at 3 and 6 months

Time frame:Baseline, Week 12 (3 months) and Week 24 (6 months)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Mass Index (BMI)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change in Glycated Hemoglobin (HbA1c)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

MASH / liver

2 endpoints
Secondary/protocol endpoint

Change in Alanine Aminotransferase (ALT)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Aspartate Aminotransferase (AST)

Time frame:Baseline, 3 months, and 6 months]

change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints
Secondary/protocol endpoint

Change in Low-Density Lipoprotein Cholesterol (LDL-C)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Triglycerides

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in High-Density Lipoprotein Cholesterol (HDL-C)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Total Cholesterol (TC)

Time frame:Baseline, 3 months, and 6 months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateNovember 5, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.